MYGN logo

Myriad Genetics (MYGN) Cash From Financing

Annual CFF

$152.90 M
+$160.90 M+2011.25%

December 1, 2023

Summary

Performance

1-Year Change

+2011.25%

3-Year Change

+7380.95%

5-Year Change

-16.13%

15-Year Change

+112.95%

MYGN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

90.78%
MYGN annual cash flow from financing activities is higher than 90.78% of companies in Healthcare sector

High & Low

All-time High

$182.30 M
MYGN annual cash flow from financing activities is currently -16.13% below its historical high of $182.30 million

3-Year Low

-$150.60 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
MYGN previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

Feb 27, 2025
MYGN next annual earnings announcement is scheduled for Feb 27, 2025

OtherMYGNcash flowmetrics:

Annual CFI

$31.90 M
MYGN annual cash flow from investing activities is $31.90 million

Annual CFO

-$110.90 M
MYGN annual cash flow from operations is -$110.90 million

Annual FCF

-$184.20 M
MYGN annual free cash flow is -$184.20 million

Annual CAPEX

$73.30 M
MYGN annual capital expenditures is $73.30 million

Quarterly CFF

-$3.10 M
-$5.50 M-229.17%

September 1, 2024

Summary

Performance

3-Month Change

-229.17%

1-Year Change

+64.77%

3-Year Change

-47.62%

5-Year Change

-381.82%

MYGN Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

15.76%
MYGN quarterly cash flow from financing activities is higher than 15.76% of companies in Healthcare sector

High & Low

All-time High

$252.10 M
MYGN quarterly cash flow from financing activities is currently -101.23% below its historical high of $252.10 million

3-Year Low

-$8.80 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
MYGN previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
MYGN next earnings announcement is scheduled for Feb 27, 2025

OtherMYGNcash flowmetrics:

Quarterly CFI

$7.50 M
MYGN quarterly cash flow from investing activities is $7.50 million

Quarterly CFO

$700.00 K
MYGN quarterly cash flow from operations is $700.00 thousand

Quarterly FCF

-$5.60 M
MYGN quarterly free cash flow is -$5.60 million

Quarterly CAPEX

$6.30 M
MYGN quarterly capital expenditures is $6.30 million

TTM CFF

$112.40 M
-$600.00 K-0.53%

September 1, 2024

Summary

Performance

3-Month Change

-0.53%

1-Year Change

-24.56%

3-Year Change

+1505%

5-Year Change

+332.23%

MYGN TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

83.54%
MYGN TTM cash flow from financing activities is higher than 83.54% of companies in Healthcare sector

High & Low

All-time High

$182.30 M
MYGN TTM cash flow from financing activities is currently -38.34% below its historical high of $182.30 million

3-Year Low

-$150.60 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
MYGN previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
MYGN next earnings announcement is scheduled for Feb 27, 2025

OtherMYGNcash flowmetrics:

TTM CFI

-$18.00 M
MYGN TTM cash flow from investing activities is -$18.00 million

TTM CFO

-$70.00 M
MYGN TTM cash flow from operations is -$70.00 million

TTM FCF

-$107.30 M
MYGN TTM free cash flow is -$107.30 million

TTM CAPEX

$37.30 M
MYGN TTM capital expenditures is $37.30 million

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

MYGN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+2011.3%+64.8%-24.6%
3 y3 years+7380.9%-47.6%+1505.0%
5 y5 years-16.1%-381.8%+332.2%

MYGN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+201.5%-102.5%+64.8%-26.5%+174.6%
5 y5-year-16.1%+201.5%-102.5%+95.8%-26.5%+174.6%
alltimeall time-16.1%+172.2%-101.2%+97.6%-38.3%+153.1%

Myriad Genetics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
-$3.10 M(-229.2%)
$112.40 M(-0.5%)
Jun 2024
-
$2.40 M(-127.3%)
$113.00 M(-24.2%)
Mar 2024
-
-$8.80 M(-107.2%)
$149.00 M(-2.6%)
Dec 2023
$152.90 M(-2011.3%)
$121.90 M(-4976.0%)
$152.90 M(+429.1%)
Sep 2023
-
-$2.50 M(-106.5%)
$28.90 M(+4.0%)
Jun 2023
-
$38.40 M(-883.7%)
$27.80 M(-443.2%)
Mar 2023
-
-$4.90 M(+133.3%)
-$8.10 M(+1.3%)
Dec 2022
-$8.00 M(-94.7%)
-$2.10 M(-41.7%)
-$8.00 M(+14.3%)
Sep 2022
-
-$3.60 M(-244.0%)
-$7.00 M(-91.0%)
Jun 2022
-
$2.50 M(-152.1%)
-$77.90 M(-27.1%)
Mar 2022
-
-$4.80 M(+336.4%)
-$106.90 M(-29.0%)
Dec 2021
-$150.60 M(+7071.4%)
-$1.10 M(-98.5%)
-$150.60 M(+0.7%)
Sep 2021
-
-$74.50 M(+181.1%)
-$149.50 M(+89.5%)
Jun 2021
-
-$26.50 M(-45.4%)
-$78.90 M(+53.5%)
Mar 2021
-
-$48.50 M(+1143.6%)
-$51.40 M(+3112.5%)
Dec 2020
-$2.10 M(-79.0%)
-
-
Sep 2020
-
-$3.90 M(-490.0%)
-$1.60 M(-84.0%)
Jun 2020
-$10.00 M(-105.5%)
$1.00 M(+400.0%)
-$10.00 M(-74.2%)
Mar 2020
-
$200.00 K(-81.8%)
-$38.80 M(-19.8%)
Dec 2019
-
$1.10 M(-108.9%)
-$48.40 M(-41.0%)
Sep 2019
-
-$12.30 M(-55.8%)
-$82.10 M(-145.0%)
Jun 2019
$182.30 M(-291.9%)
-$27.80 M(+195.7%)
$182.30 M(+8.0%)
Mar 2019
-
-$9.40 M(-71.2%)
$168.80 M(-2.9%)
Dec 2018
-
-$32.60 M(-112.9%)
$173.90 M(-3.6%)
Sep 2018
-
$252.10 M(-710.4%)
$180.40 M(-289.9%)
Jun 2018
-$95.00 M(-232.3%)
-$41.30 M(+860.5%)
-$95.00 M(-18.8%)
Mar 2018
-
-$4.30 M(-83.5%)
-$117.00 M(-21.7%)
Dec 2017
-
-$26.10 M(+12.0%)
-$149.40 M(+17.4%)
Sep 2017
-
-$23.30 M(-63.2%)
-$127.30 M(-277.3%)
Jun 2017
$71.80 M(-205.1%)
-$63.30 M(+72.5%)
$71.80 M(-19.1%)
Mar 2017
-
-$36.70 M(+817.5%)
$88.80 M(+9.0%)
Dec 2016
-
-$4.00 M(-102.3%)
$81.50 M(-33.6%)
Sep 2016
-
$175.80 M(-479.7%)
$122.70 M(-279.6%)
Jun 2016
-$68.30 M(-61.5%)
-$46.30 M(+5.2%)
-$68.30 M(+9.8%)
Mar 2016
-
-$44.00 M(-218.3%)
-$62.20 M(-16.2%)
Dec 2015
-
$37.20 M(-344.7%)
-$74.20 M(-54.7%)
Sep 2015
-
-$15.20 M(-62.2%)
-$163.70 M(-7.7%)
Jun 2015
-$177.30 M(-16.3%)
-$40.20 M(-28.2%)
-$177.30 M(-1.0%)
Mar 2015
-
-$56.00 M(+7.1%)
-$179.15 M(+49.6%)
Dec 2014
-
-$52.30 M(+81.6%)
-$119.73 M(-13.9%)
Sep 2014
-
-$28.80 M(-31.5%)
-$139.09 M(-34.3%)
Jun 2014
-$211.80 M(+162.8%)
-$42.05 M(-1329.2%)
-$211.80 M(+35.4%)
Mar 2014
-
$3.42 M(-104.8%)
-$156.41 M(-22.3%)
Dec 2013
-
-$71.66 M(-29.4%)
-$201.41 M(+38.9%)
Sep 2013
-
-$101.51 M(-861.3%)
-$144.99 M(+79.9%)
Jun 2013
-$80.60 M(+16.4%)
$13.33 M(-132.1%)
-$80.60 M(-44.8%)
Mar 2013
-
-$41.58 M(+172.9%)
-$145.96 M(+38.6%)
Dec 2012
-
-$15.24 M(-59.0%)
-$105.31 M(+21.0%)
Sep 2012
-
-$37.12 M(-28.7%)
-$87.07 M(+25.7%)
Jun 2012
-$69.25 M(-40.6%)
-$52.03 M(+5518.7%)
-$69.25 M(+842.4%)
Mar 2012
-
-$926.00 K(-130.8%)
-$7.35 M(-90.5%)
Dec 2011
-
$3.01 M(-115.6%)
-$77.23 M(-35.9%)
Sep 2011
-
-$19.30 M(-295.6%)
-$120.39 M(+3.3%)
Jun 2011
-$116.60 M(+137.5%)
$9.87 M(-113.9%)
-$116.60 M(-40.0%)
Mar 2011
-
-$70.81 M(+76.3%)
-$194.27 M(+75.1%)
Dec 2010
-
-$40.16 M(+159.0%)
-$110.97 M(+63.7%)
Sep 2010
-
-$15.50 M(-77.1%)
-$67.78 M(+38.1%)
DateAnnualQuarterlyTTM
Jun 2010
-$49.09 M(-5.5%)
-$67.80 M(-642.8%)
-$49.09 M(-55.9%)
Mar 2010
-
$12.49 M(+312.2%)
-$111.43 M(+20.8%)
Dec 2009
-
$3.03 M(-5.1%)
-$92.23 M(+6.0%)
Sep 2009
-
$3.19 M(-102.5%)
-$87.00 M(+67.5%)
Jun 2009
-$51.92 M(-337.4%)
-$130.14 M(-510.8%)
-$51.92 M(-163.6%)
Mar 2009
-
$31.68 M(+283.1%)
$81.70 M(+53.1%)
Dec 2008
-
$8.27 M(-78.4%)
$53.37 M(-0.5%)
Sep 2008
-
$38.26 M(+998.3%)
$53.64 M(+145.2%)
Jun 2008
$21.87 M(-81.4%)
$3.48 M(+3.8%)
$21.87 M(-12.9%)
Mar 2008
-
$3.36 M(-60.7%)
$25.11 M(-80.5%)
Dec 2007
-
$8.53 M(+31.4%)
$128.75 M(+4.6%)
Sep 2007
-
$6.50 M(-3.3%)
$123.14 M(+4.8%)
Jun 2007
$117.45 M(-21.7%)
$6.72 M(-93.7%)
$117.45 M(+2.8%)
Mar 2007
-
$107.00 M(+3559.4%)
$114.27 M(+931.8%)
Dec 2006
-
$2.92 M(+262.3%)
$11.07 M(-92.6%)
Sep 2006
-
$807.00 K(-77.2%)
$149.60 M(-0.2%)
Jun 2006
$149.92 M(+5979.5%)
$3.54 M(-6.9%)
$149.92 M(+1.7%)
Mar 2006
-
$3.80 M(-97.3%)
$147.48 M(+2.4%)
Dec 2005
-
$141.45 M(>+9900.0%)
$144.08 M(+4190.8%)
Sep 2005
-
$1.12 M(+1.9%)
$3.36 M(+36.2%)
Jun 2005
$2.47 M(-95.2%)
$1.10 M(+172.3%)
$2.47 M(-95.3%)
Mar 2005
-
$405.00 K(-44.2%)
$52.09 M(+0.5%)
Dec 2004
-
$726.00 K(+212.9%)
$51.81 M(+0.6%)
Sep 2004
-
$232.00 K(-99.5%)
$51.52 M(+0.4%)
Jun 2004
$51.33 M(-13.1%)
$50.73 M(>+9900.0%)
$51.33 M(+4276.2%)
Mar 2004
-
$126.00 K(-71.5%)
$1.17 M(+10.6%)
Dec 2003
-
$442.00 K(+1005.0%)
$1.06 M(-98.2%)
Sep 2003
-
$40.00 K(-92.9%)
$58.87 M(-0.3%)
Jun 2003
$59.04 M(+1660.9%)
$565.00 K(+3935.7%)
$59.04 M(+0.1%)
Mar 2003
-
$14.00 K(-100.0%)
$58.99 M(-0.3%)
Dec 2002
-
$58.25 M(>+9900.0%)
$59.15 M(+1793.4%)
Sep 2002
-
$212.00 K(-58.6%)
$3.12 M(-6.8%)
Jun 2002
$3.35 M(-95.1%)
$511.80 K(+195.5%)
$3.35 M(-36.2%)
Mar 2002
-
$173.20 K(-92.2%)
$5.26 M(-13.3%)
Dec 2001
-
$2.23 M(+404.9%)
$6.07 M(-86.9%)
Sep 2001
-
$441.00 K(-81.8%)
$46.48 M(-32.2%)
Jun 2001
$68.58 M(+80.6%)
$2.42 M(+146.1%)
$68.58 M(-24.8%)
Mar 2001
-
$982.20 K(-97.7%)
$91.15 M(-0.9%)
Dec 2000
-
$42.64 M(+89.2%)
$91.96 M(+52.5%)
Sep 2000
-
$22.54 M(-9.8%)
$60.32 M(+58.8%)
Jun 2000
$37.98 M(+9395.4%)
$24.99 M(+1292.0%)
$37.98 M(+187.8%)
Mar 2000
-
$1.79 M(-83.7%)
$13.20 M(+16.8%)
Dec 1999
-
$11.00 M(+5400.0%)
$11.30 M(+1783.3%)
Sep 1999
-
$200.00 K(0.0%)
$600.00 K(+50.0%)
Jun 1999
$400.00 K(+100.0%)
$200.00 K(-300.0%)
$400.00 K(+33.3%)
Mar 1999
-
-$100.00 K(-133.3%)
$300.00 K(0.0%)
Dec 1998
-
$300.00 K(>+9900.0%)
$300.00 K(+50.0%)
Sep 1998
-
$0.00(-100.0%)
$200.00 K(0.0%)
Jun 1998
$200.00 K(-95.3%)
$100.00 K(-200.0%)
$200.00 K(-95.2%)
Mar 1998
-
-$100.00 K(-150.0%)
$4.20 M(-8.7%)
Dec 1997
-
$200.00 K(>+9900.0%)
$4.60 M(+4.5%)
Sep 1997
-
$0.00(-100.0%)
$4.40 M(+2.3%)
Jun 1997
$4.30 M(-92.7%)
$4.10 M(+1266.7%)
$4.30 M(+2050.0%)
Mar 1997
-
$300.00 K(>+9900.0%)
$200.00 K(-300.0%)
Dec 1996
-
$0.00(-100.0%)
-$100.00 K(0.0%)
Sep 1996
-
-$100.00 K
-$100.00 K
Jun 1996
$58.90 M
-
-

FAQ

  • What is Myriad Genetics annual cash flow from financing activities?
  • What is the all time high annual CFF for Myriad Genetics?
  • What is Myriad Genetics annual CFF year-on-year change?
  • What is Myriad Genetics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Myriad Genetics?
  • What is Myriad Genetics quarterly CFF year-on-year change?
  • What is Myriad Genetics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Myriad Genetics?
  • What is Myriad Genetics TTM CFF year-on-year change?

What is Myriad Genetics annual cash flow from financing activities?

The current annual CFF of MYGN is $152.90 M

What is the all time high annual CFF for Myriad Genetics?

Myriad Genetics all-time high annual cash flow from financing activities is $182.30 M

What is Myriad Genetics annual CFF year-on-year change?

Over the past year, MYGN annual cash flow from financing activities has changed by +$160.90 M (+2011.25%)

What is Myriad Genetics quarterly cash flow from financing activities?

The current quarterly CFF of MYGN is -$3.10 M

What is the all time high quarterly CFF for Myriad Genetics?

Myriad Genetics all-time high quarterly cash flow from financing activities is $252.10 M

What is Myriad Genetics quarterly CFF year-on-year change?

Over the past year, MYGN quarterly cash flow from financing activities has changed by +$5.70 M (+64.77%)

What is Myriad Genetics TTM cash flow from financing activities?

The current TTM CFF of MYGN is $112.40 M

What is the all time high TTM CFF for Myriad Genetics?

Myriad Genetics all-time high TTM cash flow from financing activities is $182.30 M

What is Myriad Genetics TTM CFF year-on-year change?

Over the past year, MYGN TTM cash flow from financing activities has changed by -$36.60 M (-24.56%)